News
-
-
-
-
-
-
-
PRESS RELEASE
All Randomized Pediatric Patients to Continue in the Single-Blind Extension Phase of Jaguar Health's Pivotal Clinical Trial of Crofelemer for Microvillus Inclusion Disease (MVID) with Intestinal Failure (IF)
Napo Pharmaceuticals enters extension phase with blinded doses of crofelemer to support NDA filing for ultrarare pediatric disease MVID in mid-2027 -
-
-